๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

217: Evaluation of single-dose palifermin to reduce mucositis: Assessment of efficacy and safety in patients (PTS) with hematologic malignancies (HM) receiving autologous peripheral blood progenitor cell (PBPC) transplantation

โœ Scribed by T. Shea; T. Kewalramani; Y. Mun; J. Jayne; L. Dreiling

Book ID
116279398
Publisher
Elsevier Science
Year
2007
Tongue
English
Weight
70 KB
Volume
13
Category
Article
ISSN
1083-8791

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Palifermin reduces severe oral mucositis
Palifermin reduces severe oral mucositis (OM), improves patient quality of life, and reduces health resource use in patients with hematologic malignancies receiving high-dose chemotherapy (HDCT) and total body irradiation (TBI) with autologous peripheral blood stem cell (PBSC) support: results from a phase III trial
โœ W. Bensinger; D. Weisdorf; T. Gentile; A. Cesano; D. Elhardt; C. Emmanouilides; ๐Ÿ“‚ Article ๐Ÿ“… 2004 ๐Ÿ› Elsevier Science ๐ŸŒ English โš– 64 KB